Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
NCT02889133 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79
Last updated 2024-06-12
Summary
Primary Hypothesis
* The 24-hour post-transfusion RBC recovery of units obtained from donors exhibiting iron-deficient erythropoiesis will not meet FDA standards for clinical use.
* The 24-hour post-transfusion RBC recovery of units obtained after intravenous iron repletion will improve significantly and will meet FDA standards for clinical use.
Conditions
Interventions
- DRUG
-
Iron-dextran
Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
- DRUG
-
Saline
Salt water IV - 500 mL, one pint normal saline.
- PROCEDURE
-
Blood Donation
Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
- PROCEDURE
-
24-hour PTR
The way the FDA determines how good blood is for transfusion is called a "radioactive 51-Chromium 24-hour post-transfusion red cell recovery study." The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation.
Sponsors & Collaborators
-
New York Blood Center
collaborator OTHER -
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH - lead OTHER
Principal Investigators
-
Eldad A. Hod, MD · Columbia University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-01-31
- Primary Completion
- 2021-10-05
- Completion
- 2021-10-05
Countries
- United States
Study Locations
More Related Trials
-
A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge
NCT04920045 ·Status: TERMINATED ·Phase: NA
-
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
NCT00303329 ·Status: COMPLETED ·Phase: PHASE2
-
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
NCT02943668 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
NCT00110266 ·Status: COMPLETED ·Phase: PHASE2
-
Hemoglobin and Iron Recovery Study
NCT01555060 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Transfusion of Older Stored Red Cells
NCT01534676 ·Status: TERMINATED ·Phase: NA
-
Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome
NCT02262312 ·Status: COMPLETED
-
Iron Substitution in Blood Donors
NCT01519830 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
NCT00981370 ·Status: TERMINATED ·Phase: PHASE3
-
Description of Iron Status in Blood Donors
NCT00662285 ·Status: UNKNOWN ·Phase: NA
-
Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes
NCT00102245 ·Status: TERMINATED
-
Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia
NCT01309659 ·Status: TERMINATED ·Phase: PHASE2
-
Impact of Iron Injection on Blood Donation
NCT03014921 ·Status: UNKNOWN ·Phase: NA
-
IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department
NCT05153278 ·Status: COMPLETED
-
A Test of Iron Malabsorption in Patients With Iron Deficiency Anemia
NCT00399191 ·Status: COMPLETED ·Phase: PHASE1
-
IV Iron for the Anemia of Traumatic Critical Illness
NCT01180894 ·Status: COMPLETED ·Phase: NA
-
High-Tc Susceptometer to Monitor Transfusional Iron Overload
NCT01241357 ·Status: COMPLETED
-
Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure
NCT01925703 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Study of Z-213 in Subjects With Iron-deficiency Anemia
NCT02828319 ·Status: COMPLETED ·Phase: PHASE3
-
Deferoxamine for the Treatment of Hemochromatosis
NCT00001203 ·Status: COMPLETED
-
Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement
NCT02957643 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.
NCT02031289 ·Status: COMPLETED ·Phase: PHASE4
-
Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia
NCT01984554 ·Status: COMPLETED
-
Treatment of Iron Overload Requiring Chelation Therapy
NCT01927913 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00000595 ·Status: COMPLETED ·Phase: PHASE2